Global Gaucher disease treatment market to reach $1.16 billion by 2024

Sales from treatments for Gaucher disease are estimated to grow at the rate of 2.9% annually and hit $1.16 billion by 2024 from $875 million in 2014 across the seven major markets including UK, Italy, Spain, France, Germany, the US and Israel, according to research and consulting firm GlobalData.

According to the latest report from the research firm, while a lack of drugs in late-stage development will limit the expansion of the Gaucher disease treatment market by 2024, growth will be driven by an increase in the number of diagnosed prevalent Gaucher disease cases, indicating a rise in the treated population.

Edit Kovalcsik, an analyst at GlobalData, said: “This increase can be attributed to continued efforts by Genzyme and Shire to raise awareness of such a rare condition as Gaucher disease. It can also be credited to new screening programs, such as the lysosomal storage disorder new-born screening program introduced in the state of Missouri.”